Clinical Trial Search

Primary: To Evaluate Over the Aggregate IMPROVE-HF Practice Sites the Relative Changes in 7 Performance Measures at 24 Months Compared With Baseline and Determine the Number of…

Primary: Response Rate on Step 1 — 13.1; 2.6 percentage of participants

Primary: The Rate of Successful Thyroid Ablation as Defined by Negative Recombinant Human Thyrotropin (rhTSH) Stimulated Radioiodine Whole Body Scan (RAI WBS) at 1 Year. — 10; 10…

Primary: Gait Speed Before and After Real and Sham tDCS. — 8.7; 8.6; 9.7; 9.5 Seconds

Primary: Progression-free Survival — 3.9 months

Primary: Percentage of Participants With a Vital Pregnancy — 23.9; 26.9 percentage of participants

Primary: Proportion of Patients With PSA Response — 0.33; 0.24; 0.18 Proportion of participants

Primary: Normalized Accelerometric Tremor Power, Dominant Hand, 80min After Administration, Weighted Condition — 0.669; 0.798 ratio — p==0.345

Primary: Continuous 4-week Abstinence From Smoking Between Weeks 8-11 After the Quit Date (Through the End of Treatment) — 59.2; 28.3; 23.3; 16.0 percentage of subjects abstinent

Primary: Ongoing Pregnancy Rate at the End of the Study — 27.4; 30.5 percentage of randomized patient — p=0.37

Primary: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) For CP-690,550 — 183; 754; 1200 nanogram*hour per milliliter (ng*hr/mL)

Primary: Ongoing Pregnancy Rate — 40.8; 43.3 percentage of randomized patients — p=0.52

Primary: Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 — 20; 36; 38; 45 participants

Primary: Changes in Body Fat Mass(kg) — 22.9; 24.3; 22.8; 24.1 kg

Primary: Frequency of ILI(Influenza Like Illness) — 12; 22 participants